This is a preview of subscription content
Subscribe to Journal
Get full journal access for 1 year
only $9.92 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Get time limited or full article access on ReadCube.
All prices are NET prices.
Anonymized patient data is available on request from the authors.
Friedman OM, Wodinsky I, Myles A. Cyclophosphamide (NSC-26271)-related phosphoramide mustards- recent advances and historical perspective. Cancer Treat Rep. 1976;60:337–46.
Kohn FR, Sladek NE. Aldehyde dehydrogenase activity as the basis for the relative insensitivity of murine pluripotent hematopoietic stem cells to oxazaphosphorines. Biochem Pharm. 1985;34:3465–71.
Goldberg MA, Antin JH, Guinan EC, Rappeport JM. Cyclophosphamide cardiotoxicity: an analysis of dosing as a risk factor. Blood. 1986;68:1114–8.
Yeh J, Whited L, Saliba RM, Rondon G, Banchs J, Shpall E, et al. Cardiac toxicity after matched allogeneic hematopoietic cell transplant in the posttransplant cyclophosphamide era. Blood Adv. 2021;5:5599–607.
Appelbaum F, Strauchen J, Graw R, Savage D, Kent K, Ferrans V, et al. Acute lethal carditis caused by high-dose combination chemotherapy: a unique clinical and pathological entity. Orig Publ. 1976;307:58–62.
Kupari M. Cardiac involvement in bone marrow transplantation: electrocardiographic changes, arrhythmias, heart failure and autopsy findings. Bone Marrow Transpl. 1990;5:91–8.
Katayama M, Imai Y, Hashimoto H, Kurata M, Nagai K, Tamita K, et al. Fulminant fatal cardiotoxicity following cyclophosphamide therapy. J Cardiol. 2009;54:330–4.
Nakamae H, Tsumura K, Hino M, Hayashi T, Tatsumi N. QT dispersion as a predictor of acute heart failure after high-dose cyclophosphamide. Lancet. 2000;355:805–6.
Mori T, Yanagi N, Maruyama T, Gondo H, Okamura T, Kaji Y, et al. Left ventricular diastolic dysfunction induced by cyclophosphamide in blood stem cell transplantation. Jpn Heart J. 2002;43:249–61.
Löffler AI, Salerno M. Cardiac MRI for the evaluation of oncologic cardiotoxicity. J Nucl Cardiol Publ Am Soc Nucl Cardiol. 2018;25:2148–58.
Wadia S. Acute cyclophosphamide hemorrhagic myopericarditis: dilemma case report, literature review and proposed diagnostic criteria. J Clin Diagn Res JCDR. 2015;9:OE01–OE3.
Kamezaki K, Fukuda T, Makino S, Harada M. Cyclophosphamide-induced cardiomyopathy in a patient with seminoma and a history of mediastinal irradiation. Intern Med. 2005;44:120–3.
El-Sheikh A, Abdelzaher W, Gad A, Abdel-Gaber S. Purine versus non-purine xanthine oxidase inhibitors against cyclophosphamide-induced cardiac and bone marrow toxicity in rats. Hum Exp Toxicol. 2019;39:249–61.
Refaie MMM, Shehata S, El-Hussieny M, Abdelraheem WM, Bayoumi AMA. Role of ATP-sensitive potassium channel (KATP) and eNOS in mediating the protective effect of nicorandil in cyclophosphamide-induced cardiotoxicity. Cardiovasc Toxicol. 2020;20:71–81.
Pinto N, Ludeman SM, Dolan ME. Pharmacogenetic studies related to cyclophosphamide-based therapy. Pharmacogenomics. 2009;10:1897.
We thank the nursing and ancillary staff for providing excellent care for our patients and the physicians in various departments at Christian Medical College, Vellore for their significant contributions and dedicated patient care.
The authors declare no competing interests.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Selvarajan, S., Tammiraju, S., Lionel, S. et al. Cyclophosphamide induced haemorrhagic myocarditis-pericarditis: a rare but lethal complication in the setting of allogeneic stem cell transplantation. Bone Marrow Transplant (2022). https://doi.org/10.1038/s41409-022-01745-z